Literature DB >> 16579869

Mechanisms of aspirin sensitivity.

César Picado1.   

Abstract

In some asthma patients, nonsteroidal anti-inflammatory drugs (NSAIDs) induce bronchospasm, rhinorrhea, and nasal obstruction. NSAID-induced reactions appear to be caused by the inhibition of cyclooxygenase-1 (Cox-1); this in turn activates the lipoxygenase pathway, which eventually increases the release of cysteinyl leukotrienes (Cys-LTs) that induces bronchospasm and nasal obstruction. With regard to the metabolism of arachidonic acid (AA) in NSAID-intolerant asthmatic patients, the following changes have been observed: 1) A low production of prostaglandin E2, seemingly due to deficient Cox-2 regulation; 2) an increased expression of leukotriene-C4 synthase; and 3) a reduced production of metabolites (lipoxins) released through the transcellular metabolism of AA. NSAID-intolerant asthmatics have higher basal levels of Cys-LT than NSAID-tolerant asthmatics. Moreover, Cys-LT levels in NSAID-intolerant asthmatics increase remarkably following NSAID provocation testing. There has been no explanation to date that connects all these findings, although an anomaly in the regulation of Cox-2 is probably accountable.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16579869     DOI: 10.1007/s11882-006-0035-2

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.919


  27 in total

Review 1.  COX-1 sparing drugs in aspirin-sensitive asthma.

Authors:  C Picado; A Valero
Journal:  Clin Exp Allergy       Date:  2001-02       Impact factor: 5.018

2.  Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma.

Authors:  A S Cowburn; K Sladek; J Soja; L Adamek; E Nizankowska; A Szczeklik; B K Lam; J F Penrose; F K Austen; S T Holgate; A P Sampson
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

3.  Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics.

Authors:  C Picado; J C Fernandez-Morata; M Juan; J Roca-Ferrer; M Fuentes; A Xaubet; J Mullol
Journal:  Am J Respir Crit Care Med       Date:  1999-07       Impact factor: 21.405

4.  Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients.

Authors:  M L Kowalski; R Pawliczak; J Wozniak; K Siuda; M Poniatowska; J Iwaszkiewicz; T Kornatowski; M A Kaliner
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

5.  Dynamics of COX-2 in nasal mucosa and nasal polyps from aspirin-tolerant and aspirin-intolerant patients with asthma.

Authors:  Laura Pujols; Joaquim Mullol; Isam Alobid; Jordi Roca-Ferrer; Antoni Xaubet; César Picado
Journal:  J Allergy Clin Immunol       Date:  2004-10       Impact factor: 10.793

Review 6.  Molecular and functional aspects of human cysteinyl leukotriene receptors.

Authors:  Valérie Capra
Journal:  Pharmacol Res       Date:  2004-07       Impact factor: 7.658

7.  Protective effects of inhaled PGE2 on allergen-induced airway responses and airway inflammation.

Authors:  G M Gauvreau; R M Watson; P M O'Byrne
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

8.  Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics.

Authors:  M Kumlin; B Dahlén; T Björck; O Zetterström; E Granström; S E Dahlén
Journal:  Am Rev Respir Dis       Date:  1992-07

9.  Urinary leukotriene E4 in bronchial asthma.

Authors:  C M Smith; R J Hawksworth; F C Thien; P E Christie; T H Lee
Journal:  Eur Respir J       Date:  1992-06       Impact factor: 16.671

10.  Release of peptide leukotriene into nasal secretions after local instillation of aspirin in aspirin-sensitive asthmatic patients.

Authors:  C Picado; I Ramis; J Rosellò; J Prat; O Bulbena; V Plaza; J M Montserrat; E Gelpí
Journal:  Am Rev Respir Dis       Date:  1992-01
View more
  6 in total

Review 1.  Hypersensitivity to Aspirin and other NSAIDs: Diagnostic Approach in Patients with Chronic Rhinosinusitis.

Authors:  Joanna Makowska; Anna Lewandowska-Polak; Marek L Kowalski
Journal:  Curr Allergy Asthma Rep       Date:  2015-08       Impact factor: 4.806

2.  Quinidine, but not eicosanoid antagonists or dexamethasone, protect the gut from platelet activating factor-induced vasoconstriction, edema and paralysis.

Authors:  Ingmar Lautenschläger; Inéz Frerichs; Heike Dombrowsky; Jürgen Sarau; Torsten Goldmann; Karina Zitta; Martin Albrecht; Norbert Weiler; Stefan Uhlig
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

3.  Signal transduction pathways (MAPKs, NF-κB, and C/EBP) regulating COX-2 expression in nasal fibroblasts from asthma patients with aspirin intolerance.

Authors:  Francesc Josep Garcia-Garcia; Joaquim Mullol; Maria Perez-Gonzalez; Laura Pujols; Isam Alobid; Jordi Roca-Ferrer; Cesar Picado
Journal:  PLoS One       Date:  2012-12-11       Impact factor: 3.240

Review 4.  The clinical effectiveness of aspirin desensitization in chronic rhinosinusitis.

Authors:  Adam N Williams; Katharine M Woessner
Journal:  Curr Allergy Asthma Rep       Date:  2008-05       Impact factor: 4.919

5.  COX-1, and not COX-2 activity, regulates airway function: relevance to aspirin-sensitive asthma.

Authors:  Louise S Harrington; Ruth Lucas; Shaun K McMaster; Laura Moreno; Glenis Scadding; Timothy D Warner; Jane A Mitchell
Journal:  FASEB J       Date:  2008-08-27       Impact factor: 5.191

Review 6.  Cough and viruses in airways disease: mechanisms.

Authors:  Joseph Footitt; Sebastian L Johnston
Journal:  Pulm Pharmacol Ther       Date:  2009-04       Impact factor: 3.410

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.